Skip to main content
Erschienen in:

23.03.2020 | Original Article

Holmium laser enucleation of the prostate for very large benign prostatic hyperplasia (≥ 200 cc)

verfasst von: Michael A. Zell, Haidar Abdul-Muhsin, Anojan Navaratnam, Jameson Cumsky, Marlene Girardo, Joseph Cornella, Amihay Nevo, Scott Cheney, Mitchell R. Humphreys

Erschienen in: World Journal of Urology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients presenting with prostate gland sizes greater than 200 cc pose a unique surgical challenge to both patients and surgeons. The objective of this study is to critically assess the efficacy and risks associated with performing holmium laser enucleation of the prostate (HoLEP) on glands ≥ 200 cc.

Materials and methods

Using a prospective maintained database, all consecutive benign prostatic hyperplasia (BPH) patients with gland size ≥ 200 cc who underwent HoLEP were included. We reported patient preoperative, intraoperative, postoperative outcomes and complications. Subgroup analysis of outcomes was stratified by gland sizes 200–299 cc and ≥ 300 cc. Univariate analysis using Kruskal–Wallis and Fisher exact test was performed to compare the two groups.

Results

There were 88 patients with a mean preoperative gland size of 255.9 cc (200–770 cc). Mean operative (171 vs 182 min) and enucleation time (77 vs 83 min) were not different between the two subgroups (200–299 cc vs ≥ 300 cc). Enucleation efficiency was greater for glands ≥ 300 cc (2.6 cc/min vs 2.0 cc/min, p = 0.04). Morcellation time was longer in the ≥ 300 cc group (74.5 min vs 46.8 min, p = 0.021). Mean length of stay was 1.8 ± 1.2 days and catheter duration was 2.6 ± 2.7 days. 1 (1.1%) patient required retreatment of BPH at last follow-up. The main limitation of this study is the retrospective data analysis.

Conclusions

Holmium laser enucleation for prostate glands volume > 200 cc is feasible with minimal morbidity. These data further reinforce the size independence success of this procedure for BPH.
Literatur
1.
Zurück zum Zitat Mather M, Jacobsen LA, Pollard KM (2015) Aging in the united states. 2015: Population Reference Bureau. Mather M, Jacobsen LA, Pollard KM (2015) Aging in the united states. 2015: Population Reference Bureau.
2.
Zurück zum Zitat Filson CP, Wei JT, Hollingsworth JM (2013) Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 82(6):1386–1393CrossRef Filson CP, Wei JT, Hollingsworth JM (2013) Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 82(6):1386–1393CrossRef
3.
Zurück zum Zitat Elshal AM et al (2013) Transvesical open prostatectomy for benign prostatic hyperplasia in the era of minimally invasive surgery: perioperative outcomes of a contemporary series. Arab J Urol 11(4):362–368CrossRef Elshal AM et al (2013) Transvesical open prostatectomy for benign prostatic hyperplasia in the era of minimally invasive surgery: perioperative outcomes of a contemporary series. Arab J Urol 11(4):362–368CrossRef
4.
Zurück zum Zitat Groves HK et al (2013) The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis 16(3):260–265CrossRef Groves HK et al (2013) The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis 16(3):260–265CrossRef
5.
Zurück zum Zitat Humphreys MR et al (2008) Holmium laser enucleation of the prostate: outcomes independent of prostate size? J Urol 180(6):2431–2435 (Discussion 2435)CrossRef Humphreys MR et al (2008) Holmium laser enucleation of the prostate: outcomes independent of prostate size? J Urol 180(6):2431–2435 (Discussion 2435)CrossRef
6.
Zurück zum Zitat Jones P et al (2016) Holmium laser enucleation versus simple prostatectomy for treating large prostates: results of a systematic review and meta-analysis. Arab J Urol 14(1):50–58CrossRef Jones P et al (2016) Holmium laser enucleation versus simple prostatectomy for treating large prostates: results of a systematic review and meta-analysis. Arab J Urol 14(1):50–58CrossRef
7.
Zurück zum Zitat Krambeck AE, Handa SE, Lingeman JE (2010) Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol 24(3):433–437CrossRef Krambeck AE, Handa SE, Lingeman JE (2010) Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol 24(3):433–437CrossRef
8.
Zurück zum Zitat Gratzke C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109CrossRef Gratzke C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109CrossRef
9.
Zurück zum Zitat HE F et al (2019) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE. HE F et al (2019) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE.
10.
Zurück zum Zitat Gilling PJ, Kennett KM, Fraundorfer MR (2000) Holmium laser enucleation of the prostate for glands larger than 100 g: an endourologic alternative to open prostatectomy. J Endourol 14(6):529–531CrossRef Gilling PJ, Kennett KM, Fraundorfer MR (2000) Holmium laser enucleation of the prostate for glands larger than 100 g: an endourologic alternative to open prostatectomy. J Endourol 14(6):529–531CrossRef
11.
Zurück zum Zitat Glybochko PV et al (2017) Holmium laser enucleation of the prostate (HoLEP) for small, large and giant prostatic hyperplasia: tips and tricks. Urologia 84(3):169–173CrossRef Glybochko PV et al (2017) Holmium laser enucleation of the prostate (HoLEP) for small, large and giant prostatic hyperplasia: tips and tricks. Urologia 84(3):169–173CrossRef
12.
Zurück zum Zitat Yuh B et al (2008) Robot-assisted Millin’s retropubic prostatectomy: case series. Can J Urol 15(3):4101–4105PubMed Yuh B et al (2008) Robot-assisted Millin’s retropubic prostatectomy: case series. Can J Urol 15(3):4101–4105PubMed
13.
Zurück zum Zitat Kuntz RM, Lehrich K, Ahyai S (2004) Transurethral holmium laser enucleation of the prostate compared with transvesical open prostatectomy: 18-month follow-up of a randomized trial. J Endourol 18(2):189–191CrossRef Kuntz RM, Lehrich K, Ahyai S (2004) Transurethral holmium laser enucleation of the prostate compared with transvesical open prostatectomy: 18-month follow-up of a randomized trial. J Endourol 18(2):189–191CrossRef
14.
Zurück zum Zitat Monn MF et al (2015) Predictors of enucleation and morcellation time during holmium laser enucleation of the prostate. Urology 86(2):338–342CrossRef Monn MF et al (2015) Predictors of enucleation and morcellation time during holmium laser enucleation of the prostate. Urology 86(2):338–342CrossRef
15.
Zurück zum Zitat El Tayeb MM et al (2016) Wolf piranha Versus lumenis versacut prostate morcellation devices: a prospective randomized trial. J Urol 195(2):413–417CrossRef El Tayeb MM et al (2016) Wolf piranha Versus lumenis versacut prostate morcellation devices: a prospective randomized trial. J Urol 195(2):413–417CrossRef
16.
Zurück zum Zitat McAdams S et al (2017) Morcellation efficiency in holmium laser enucleation of the prostate: oscillating morcellator outperforms reciprocating morcellator with no apparent learning curve. Urology 106:173–177CrossRef McAdams S et al (2017) Morcellation efficiency in holmium laser enucleation of the prostate: oscillating morcellator outperforms reciprocating morcellator with no apparent learning curve. Urology 106:173–177CrossRef
17.
Zurück zum Zitat Tubaro A, de Nunzio C (2006) The current role of open surgery in BPH. EAU-EBU Update Ser 4(5):191–201CrossRef Tubaro A, de Nunzio C (2006) The current role of open surgery in BPH. EAU-EBU Update Ser 4(5):191–201CrossRef
18.
Zurück zum Zitat Xing N et al (2012) Laparoscopic simple prostatectomy with prostatic urethra preservation for benign prostatic hyperplasia. Transl Androl Urol 1(1):9–13PubMedPubMedCentral Xing N et al (2012) Laparoscopic simple prostatectomy with prostatic urethra preservation for benign prostatic hyperplasia. Transl Androl Urol 1(1):9–13PubMedPubMedCentral
19.
Zurück zum Zitat Sosnowski R et al (2014) Endoscopic simple prostatectomy. Central Eur J Urol 67(4):377–384 Sosnowski R et al (2014) Endoscopic simple prostatectomy. Central Eur J Urol 67(4):377–384
20.
Zurück zum Zitat Shah AA, Gahan JC, Sorokin I (2018) Comparison of robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep 19(9):71CrossRef Shah AA, Gahan JC, Sorokin I (2018) Comparison of robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep 19(9):71CrossRef
21.
Zurück zum Zitat Parsons JK et al (2015) A national, comparative analysis of perioperative outcomes of open and minimally invasive simple prostatectomy. J Endourol 29(8):919–924CrossRef Parsons JK et al (2015) A national, comparative analysis of perioperative outcomes of open and minimally invasive simple prostatectomy. J Endourol 29(8):919–924CrossRef
22.
Zurück zum Zitat Kyei MY et al (2016) Determinants of peri-operative blood transfusion in a contemporary series of open prostatectomy for benign prostate hyperplasia. BMC Urol 16:17CrossRef Kyei MY et al (2016) Determinants of peri-operative blood transfusion in a contemporary series of open prostatectomy for benign prostate hyperplasia. BMC Urol 16:17CrossRef
23.
Zurück zum Zitat Suer E et al (2008) Open prostatectomy is still a valid option for large prostates: a high-volume, single-center experience. Urology 72(1):90–94CrossRef Suer E et al (2008) Open prostatectomy is still a valid option for large prostates: a high-volume, single-center experience. Urology 72(1):90–94CrossRef
24.
Zurück zum Zitat Rassweiler J et al (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50(5):969–980CrossRef Rassweiler J et al (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50(5):969–980CrossRef
25.
Zurück zum Zitat Serretta V et al (1990s) Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology 60(4):623–627CrossRef Serretta V et al (1990s) Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. Urology 60(4):623–627CrossRef
26.
Zurück zum Zitat Matlaga BR et al (2006) Holmium laser enucleation of the prostate for prostates of %3e125 mL. BJU Int 97(1):81–84CrossRef Matlaga BR et al (2006) Holmium laser enucleation of the prostate for prostates of %3e125 mL. BJU Int 97(1):81–84CrossRef
Metadaten
Titel
Holmium laser enucleation of the prostate for very large benign prostatic hyperplasia (≥ 200 cc)
verfasst von
Michael A. Zell
Haidar Abdul-Muhsin
Anojan Navaratnam
Jameson Cumsky
Marlene Girardo
Joseph Cornella
Amihay Nevo
Scott Cheney
Mitchell R. Humphreys
Publikationsdatum
23.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2021
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-020-03156-5

Neu im Fachgebiet Urologie

Hohe Atrophierate nach Hodentorsion im Kindesalter

Auf längere Sicht ist die Atrophierate nach einer Hodentorsion pädiatrischer Patienten erschreckend hoch. Das hat eine Studie mit jahrelanger Nachbeobachtung ergeben. Entscheidend ist die Zeit, die bis zur Detorsion verstreicht.

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

"Die Erektionsstörung ist keine isolierte Erkrankung"

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.